26 news items
Page 2 of 2
b9q18xx0f146846dhmrc4imihapee 9f4js31q
ADPT
ADSK
ALXO
17 Apr 24
analyst Hartaj Singh maintained Viracta Therapeutics with an Outperform and maintained a $13 price target.
Spectaire Holdings Inc
wgu7fmbikc7ph7ie0ti6e19bt4t aozvm1n60xfy
SAGE
17 Apr 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $28 price target.
ix2 csxrmg
SAGE
17 Apr 24
Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $24 price target.
3e5xdo77bg8hz1x7j2bi
SAGE
17 Apr 24
(NASDAQ:SAGE) from Neutral to Underperform and lowers the price target from $24 to $14.
a66kfniaf w8pw2jojj8nmefvncbak15r2kpqsg2utg
SAGE
17 Apr 24
and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out
rh4hunjjd67hwegaa1ghybe6q6zxd80yl82c9g 8z0jfullvfp4l
SAGE
11 Apr 24
depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find